TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05064527

Intervention type: DEVICE
Intervention: wearable biosensor
Description: The E4 wristband will be worn by all groups for the duration of the study. It measures blood volume pulse, electrodermal activity, skin temperature, and movement. Patients will be asked to press the event tagging button when they feel stressed by OCD. Control will be asked to press the button when they feel anxious. Parents will be asked to press the button with they notice their child feels stressed by OCD or anxious.

Intervention type: DEVICE
Intervention: wearable biosensor
Description: The E4 wristband will be worn by all groups for the duration of the study. It measures blood volume pulse, electrodermal activity, skin temperature, and movement. Patients will be asked to press the event tagging button when they feel stressed by OCD. Control will be asked to press the button when they feel anxious. Parents will be asked to press the button with they notice their child feels stressed by OCD or anxious.

Intervention type: DEVICE
Intervention: wearable biosensor
Description: The E4 wristband will be worn by all groups for the duration of the study. It measures blood volume pulse, electrodermal activity, skin temperature, and movement. Patients will be asked to press the event tagging button when they feel stressed by OCD. Control will be asked to press the button when they feel anxious. Parents will be asked to press the button with they notice their child feels stressed by OCD or anxious.

Intervention type: DEVICE
Intervention: wearable biosensor
Description: The E4 wristband will be worn by all groups for the duration of the study. It measures blood volume pulse, electrodermal activity, skin temperature, and movement. Patients will be asked to press the event tagging button when they feel stressed by OCD. Control will be asked to press the button when they feel anxious. Parents will be asked to press the button with they notice their child feels stressed by OCD or anxious.

Intervention type: BEHAVIORAL
Intervention: Treatment as usual (TAU)
Description: Patients will receive treatment as usual at the child and adolescent mental health center. TAU can range from waitlist to one session of psychoeducation to group or individual psychotherapy to medication.

Intervention type: BEHAVIORAL
Intervention: Exposure and response prevention (ERP)
Description: One ERP session will be offered in Week 0 and Week 8.
Study: NCT05415670

Intervention type: DIAGNOSTIC_TEST
Intervention: Whole-genome Methylation Sequencing(GM-seq)
Description: A Whole-genome Methylation detection method, which can analyze the genome-wide, single base resolution methylation of tissue / blood samples, and is used to develop a benign and malignant classification model for Pulmonary Nodule.

Intervention type: DIAGNOSTIC_TEST
Intervention: Whole-genome Methylation Sequencing(GM-seq)
Description: A Whole-genome Methylation detection method, which can analyze the genome-wide, single base resolution methylation of tissue / blood samples, and is used to develop a benign and malignant classification model for Pulmonary Nodule.
Study: NCT04799743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: Resveratrol has been used as a food supplement. Its antiviral properties have been well studied including its inhibitory effect against the coronavirus MERS-CoV. Our previous in vitro and in vivo studies found that the compound had other health benefits such as anti-fibrotic effect.The anti-fibrotic effect will add an extra benefit for resveratrol to fight against COVID-19 as lungs are the most affected organs by the coronavirus, which may result in prolonged fibrotic damage of the lungs even when a patient is recovered from the COVID-19 disease.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: The placebo consist of mainly starch and microcrystalline cellulose, the usage and dosage are the same as the investigational drug.
Study: NCT04476251

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: E7 T-Cell Receptor (TCR)
Description: Patients will receive up to 3x10\^10 E7 T-Cell Receptor (TCR) T cells (i.e. TCR+ cells).
Study: NCT04449328

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computerized Mirror Therapy (CMT)
Description: Computerized Mirror Therapy (CMT) will be realizing by the device Intensive Visual Simulation 3 (IVS3).~The patient looks on a screen in front of him, mirroring the movements made by his hand, while attempting to perform the same movement with his other hand.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Computerized Mirror Therapy (CMT)
Description: Computerized Mirror Therapy (CMT) will be realizing by the device Intensive Visual Simulation 3 (IVS3).~The patient looks on a screen in front of him, mirroring the movements made by his hand, while attempting to perform the same movement with his other hand.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tendon vibration
Description: Transcutaneous vibrations are used. This device allows vibrations from 50 to 120 Hz with amplitude of 1 mm. This study the frequency used is 70 and 80 Hz.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Tendon vibration
Description: Transcutaneous vibrations are used. This device allows vibrations from 50 to 120 Hz with amplitude of 1 mm. This study the frequency used is 70 and 80 Hz.
Study: NCT04613232

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable sensor
Description: The patients will be asked to wear an Apple Watch during their treatment course. The watch will pasively collect sensor data (heart rate and physical activity)
Study: NCT04734652

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Biktarvy®
Description: Biktarvy® is a fixed dose combination, single tablet containing bictegravir (BIC), emtricitabine (FTC), and tenofovir alafenamide (TAF) for oral administration.~BIC is an integrase strand transfer inhibitor (INSTI). FTC, a synthetic nucleoside analog of cytidine, is an HIV nucleoside analog reverse transcriptase inhibitor (HIV NRTI). TAF, an HIV NRTI, is converted in vivo to tenofovir, an acyclic nucleoside phosphonate (nucleotide) analog of adenosine 5'-monophosphate. Each tablet contains 50 mg of BIC (equivalent to 52.5 mg of bictegravir sodium), 200 mg of FTC, and 25 mg of TAF (equivalent to 28 mg of tenofovir alafenamide fumarate) and the following inactive ingredients: croscarmellose sodium, magnesium stearate, and microcrystalline cellulose.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: TLD- fixed-drug combination single tablet
Description: Standard of care Dolutegravir-based regimen
Study: NCT05870839

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VXCO-100
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VXCO-100
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VXCO-100
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VXCO-100
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VXCO-100
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VXCO-100
Description: Sterile liquid for injection
Study: NCT06632756

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual and Group Treatment for Smoking Cessation
Description: Positive psychology-based individual treatment and groups
Study: NCT03250923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: silver citrate complex and acemannan
Description: Oral rinse solution with each dose containing 100μg silver citrate complex and 40mg acemannan
Study: NCT05154981

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education communication skills (ECS) training
Description: Education communication skills (ECS) training videos were developed from LEAPS (Listen, Educate, Assess, Partner and Support), a set of 10- to 20- sec videos that help patients and physicians communicate health concerns and treatment plans to each other. ECS training videos target parent-teacher communication during the transition to school for children with autism.
Study: NCT05402956

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Moderate aerobic exercise training
Study: NCT06472947

Intervention type: DEVICE
Intervention: ULM and MSOT
Description: transplanted kidney will be examined non-invasively with ULM and MSOT
Study: NCT06122350

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Earthquake preparedness training
Description: Mothers with physically disabled children will be trained on what to do before, during and after an earthquake within the scope of earthquake preparedness training.
Study: NCT06542367

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tympanoplasty performed under local anesthesia using fat graft and Tachosil.
Description: Under local anesthesia, subcutaneous fat from the neck will be harvested. After that trimming of the perforation edges, planting the fat graft medial to the tympanic membrane and placement of the Tachosil on top of the fat graft.~gelfoam is placed lateral to the tympanic membrane to fill the ear canal. follow-up will be held at 2, 4-6 and 12 months following the procedure, with audiometric and otological evaluation
Study: NCT05232552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib hydrochloride
Description: anlotinib was administered orally 12mg daily for 14 days concurrent with inductive chemotherapy (TP ) for 3 cycles and definitive chemoradiation for additional 2 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: induction chemotherapy
Description: docetaxel 75mg/m2 d1 plus DDP 75mg/m2 d1 for 3 cycles every 21days

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: concurrent chemoradiation
Description: definitive IMRT (GTV\>66Gy) concurrent with 2 cycles of DDP (100mg/m2 d1) and anlotinib (12mg d1-14) every 21 days
Study: NCT04752371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camoteskimab (CERC-007, AVTX-007, AEVI-007)
Description: Intravenous (IV) Infusion
Study: NCT05154981

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Partners in School
Description: Partners in School is a problem-solving consultation that encourages parents and teachers to implement the same evidence-based interventions across home and school

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Partners in School
Description: Partners in School is a problem-solving consultation that encourages parents and teachers to implement the same evidence-based interventions across home and school
Study: NCT06151899

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio taping with angle and tension
Description: Kinesio taping by applying angle and tension to back muscle
Study: NCT05141500

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STRYKER SUSTAINABILITY SOLUTIONS PULSE OXIMETERS
Description: Reprocessed noninvasive pulse oximeters~* 1859 \& 2329~* MAX-A \& MAX-N
Study: NCT05107128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-718
Description: Oral capsules.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SAGE-718-matching oral capsules.
Study: NCT06319716

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video-Based Diabetes Self-Management Education and Support (DSMES)
Description: The DSMES videos provide important diabetes education to participants and empower them to become an activated patient on the individual level.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video-Based Diabetes Self-Management Education and Support (DSMES)
Description: The DSMES videos provide important diabetes education to participants and empower them to become an activated patient on the individual level.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Health Worker (CHW) Support
Description: CHWs will assess participants' social determinants of health (SDOH) barriers to Type 2 diabetes care and link them to available resources in the community.
Study: NCT06380296

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Primary molars pulpotomies with NeoMTA
Description: Primary molar pulpotomies will be performed by trained dentists using NeoMTA, a bioactive material containing calcium silicate known for its bio-active and bone forming potential. Follow-up visits at 1, 6, 12 and 24 months will be conducted to assess success rate, and clinical and radiographic outcomes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Primary molar pulpotomies with NeoPUTTY
Description: Primary molar pulpotomies will be performed by trained dentists using NeoPUTTY, a ready to use bioactive material containing calcium silicate. Follow-up visits at 1, 6, 12 and 24 months will be conducted to assess success rate, and clinical and radiographic outcomes
Study: NCT04744545

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Meru Health Program
Description: 12 week evidence-based mental health intervention overseen by a licensed clinical therapist delivered via Smartphone app

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meru Health Program
Description: 12 week evidence-based mental health intervention overseen by a licensed clinical therapist delivered via Smartphone app
Study: NCT04744545

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: 1500mg/day curcumin plus black pepper to aid absorption
Study: NCT05676229

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic blend
Description: Lactobacillus gasseri CCT 7850 and Bifidobacterium lactis CCT 7858

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin only (vehicle)
Study: NCT06252935

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FormaAid
Description: FormaAid is mainly composed of pure collagen extracted from bovine tendon, it is fabricated in the form of highly dense collagen matrix without chemical cross-linking to act as a barrier excluding epithelium.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bio-Gide
Description: Bio-Gide is a bilayer collagen membrane made of porcine collagen, permits prompt and homogeneous vascularization and so brings about optimal tissue integration and wound stabilization.
Study: NCT05508373

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JS019
Description: Four dose levels are preset: 0.3 mg/kg, 1 mg/kg, 3 mg/kg, and 10 mg/kg. The subjects are treated with JS019 by intravenous infusion, once every 3 weeks (Q3W). A treatment cycle is 21 days, and the DLT observation period is 21 days after the first administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JS019
Description: Four dose levels are preset: 0.3 mg/kg, 1 mg/kg, 3 mg/kg, and 10 mg/kg. The subjects are treated with JS019 by intravenous infusion, once every 3 weeks (Q3W). A treatment cycle is 21 days, and the DLT observation period is 21 days after the first administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JS019
Description: Four dose levels are preset: 0.3 mg/kg, 1 mg/kg, 3 mg/kg, and 10 mg/kg. The subjects are treated with JS019 by intravenous infusion, once every 3 weeks (Q3W). A treatment cycle is 21 days, and the DLT observation period is 21 days after the first administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JS019
Description: Four dose levels are preset: 0.3 mg/kg, 1 mg/kg, 3 mg/kg, and 10 mg/kg. The subjects are treated with JS019 by intravenous infusion, once every 3 weeks (Q3W). A treatment cycle is 21 days, and the DLT observation period is 21 days after the first administration.
Study: NCT05648799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP30341 capsules 200 mg
Description: orall take of capsules twice a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy
Description: Standard medicines for treatment of a new coronavirus infection 2019 (COVID-19).
Study: NCT06153342

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TL-925
Description: TL-925 is an eye drop.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The composition of the placebo is identical to the active formulation except for the exclusion of the active ingredient.
Study: NCT05401006

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acitretin 25Mg Cap
Description: Acitretin is an oral retinoid (a derivative of vitamin A) given in a dose 0.25-1 mg /kg/day for 3months in psoriatic patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acitretin 25Mg Cap
Description: Acitretin is an oral retinoid (a derivative of vitamin A) given in a dose 0.25-1 mg /kg/day for 3months in psoriatic patients

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Narrowband ultraviolet B
Description: Narrowband UVB is the most common form of phototherapy used to treat psoriasis, given 2-3 sessions per week for 3 successive months

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Narrowband ultraviolet B
Description: Narrowband UVB is the most common form of phototherapy used to treat psoriasis, given 2-3 sessions per week for 3 successive months
Study: NCT04903392

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Backward Walking Training
Description: The training speed will start at the basic walking speed and will increase by 5% of the starting speed each week. The training, which will take 30 minutes, will be as follows: 5 minutes forward walking (warm-up phase), 20 minutes backward walking (intervention phase) and 5 minutes forward (cooling phase).~-three times a week for six weeks

Intervention type: OTHER
Group type: OTHER
Intervention: Forward Walking Training
Description: The training speed will start at the basic walking speed and will increase by 5% of the starting speed each week. It will be in the form of walking forward for 30 minutes.~-three times a week for six weeks
Study: NCT05310422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivanisiran sodium ophthalmic solution
Description: 1 drop in the affected eye(s) once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle ophthalmic solution
Description: 1 drop in the affected eye(s) once daily
Study: NCT06395818

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: prefabricated CAD-CAM allogeneic bone block hydrated using hyaluronic acid
Description: exposure of atrophic posterior mandibular ridge, augmentation with CAD-CAM prefabricated allogenic bone block which fixed with titanium screws ,The block was coated with a nonporous d-PTFE membrane

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: prefabricated CAD-CAM allogeneic bone block sterilized hydrated using saline solution
Description: exposure of atrophic posterior mandibular ridge, augmentation with CAD-CAM prefabricated allogenic bone block which fixed with titanium screws. The block was coated with a nonporous d-PTFE membrane
Study: NCT04833127

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gender-Enhanced -- Masibambane
Description: The intervention has components that provide PrEP information, provide information about HIV prevention and contraceptive options, prompt women to think about why they may be at risk for HIV, discuss women's sexual rights, and discuss how women can talk to their male partners about PrEP. The components are conducted by participants on their own time as well as during a real-time live interactive session with trained facilitators.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Individually accessed
Description: The intervention includes an individually-accessed online PrEP video and South African government websites on PrEP and on contraception options
Study: NCT06634823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide Injectable Suspension
Description: Triamcinolone injection into deltoid muscle (arm)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline injection
Description: Saline injection into deltoid muscle (arm)
Study: NCT05374200

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mind-body intervention with 1-1 support from study personnel
Description: The multicomponent intervention will consist of the following core components: (1) A choice between three different types of low-intensity, mindful movement videos - chair fitness, standing fitness, or standing tai chi (15-30 minutes/session); (2) Breathwork and theme-of-the-week based mindfulness meditations (5-10 minutes/session); (3) A once weekly positive psychology/behavior change activity presented as a point-and-click interactive storybook within the online site; (4) A once weekly disease management tip from a PBC physician.~Weekly brief (\~10-minute) motivational interview style telephone check-ins taking place during the intervention period will be conducted by a member of the study team. During these check-ins, progress will be reviewed, motivation provided, and questions answered.
Study: NCT05113368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Oral regorafenib in a ReDOSplan (80 mg week#1, 120 mg week#2, 160 mg week#3 for cycle #1 then adjust final dose for subsequent cycles based on tolerance during cycle #1) \[3 weeks on/1 week off\] combined with intramuscular injection of fulvestrant 500 mg day #1 (day #15 will be planned only in cycle #1) in a 28-day cycle till disease progression or unacceptable toxicities

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 500 mg day #1 (day #15 will be planned only in cycle #1) in a 28-day cycle till disease progression or unacceptable toxicities
Study: NCT06436443

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SMS Counseling
Description: In addition to routine physician check-ups, an SMS group was created for the individuals in the intervention group, and basic information messages for diabetes control were sent to this group at regular intervals. In addition, individuals asked questions via this group. At the end of the eight-week follow-up, the data collection forms were filled out again and the study was terminated.
Study: NCT05527652

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self-Supporting Nasopharyngeal Airway (ssNPA)
Description: The ssNPA device is made of a single piece of flexible, medical-grade silicone. It is inserted through one nostril and extends to the anatomic position bypassing the upper airway obstruction above the epiglottis.
Study: NCT04538911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCG-PPD
Description: BCG-PPD was used for skin test in 30 TB patients, and BCG-PPD was marketed in other 30 TB patients (as control)

Intervention type: DRUG
Group type: OTHER
Intervention: BCG-PPD
Description: BCG-PPD was used for skin test in 30 TB patients, and BCG-PPD was marketed in other 30 TB patients (as control)